Silence Therapeutics plc (SLN)

Market Cap	294.27M +28.7%
Revenue (ttm)	839,000 -97.0%
Net Income	-75.04M
EPS	-1.61
Shares Out	47.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,400
Open	6.24
Previous Close	6.17
Day's Range	6.02 - 6.31
52-Week Range	4.19 - 8.40
Beta	1.48
Analysts	Buy
Price Target	31.20 (+400.8%)
Earnings Date	May 7, 2026

About SLN

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN3...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 88
• Stock Exchange: NASDAQ
• Ticker Symbol: SLN
• Website: https://www.silence-therapeutics.com

Financial Performance

In 2025, Silence Therapeutics's revenue was $559,000, a decrease of -98.71% compared to the previous year's $43.26 million. Losses were -$88.61 million, 95.6% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for SLN stock is "Buy." The 12-month stock price target is $31.2, which is an increase of 400.80% from the latest price.

Price Target

$31.2

(400.80% upside)

Analyst Consensus: Buy